Sunday , October 17 2021

She gets Scheelepriset – Life Science Sweden

– I am pleased that the prestigious award of the Pharmaceutical Association has been said Emmanuelle Charpentier in a press release, and she expects to visit Stockholm in November to receive a prize.

Price consists of cash prize of SEK 225,000 and medal. Together with the award ceremony of November 28, 2019, a symposium will be held, with a theme related to the laureate's research.

Professor Charpentier is a real newcomer whose research may mean a real paradigm shift when it comes to biomedical gene therapy for a number of complex diseases, says: Karin Meyer, Head of Pharmaceutical Association and Chairman of Nomination Committee.

Emmanuelle Charpentier is awarded prize with the following motivation: "To contribute to the understanding and relevance of the molecular mechanism of the Crispr-Cas9 system – a genetic instrument with many applications for drug research and development".

– I am particularly pleased that the Prize Committee draws attention to the role of our fundamental research in the regulation of genes in micro-organisms, as it has laid the foundations for the development of Crispr-Cas9 technology and its applications; Emmanuelle Charpentier.

Emmanuelle Charpentier, director of her own institute today, Max Planck The Berlin Pathogen Science Department is one of the pioneers and mechanisms of short-ribonucleic acid sequences that are pathogenic bacteria-regulating bacteria, the small RNA. Studying Crispr-Cas9, she developed new genetic engineering tools that can serve as a basis for new medical procedures, in addition to many applications in life sciences. There are high hopes that Crispr-Cas9 therapy methods can cure various complicated genetic diseases in the future.

In his time as a researcher and group leader in laboratory molecular infection medicine in Sweden, MIMS, Umeå University, she discovered details about the Crispr-Cas9 system. In some pathogenic streptococci, Cas9 is found to act as a bacterial immune system against viral attacks. For Cas9 to find and divide viral DNA, information is stored in bacterial DNA gene sequences. The information is called Crispr, which means that the clusters are repeated regularly for a short time. Slightly simpler, Crispr acts as a copy of a DNA copy of a working DNA part of a virus that is used by a bacterial cell to form companions in the form of short RNA molecules that help the Cas9 enzyme find the DNA of the virus to cut it.

Charpentier and her staff could prove that Crispr-Cas9 requires three players: Cas9, tracrRNA and Crispr-RNA. Their main findings were published in Nature 2011 and Science 2012, which led to a variety of applications in fundamental research in molecular biology and biomedicine, as technology turned out to work not only in bacterial cells but also in all types of cells. This tool is called popular science "gene scissors" and has opened up completely new paths for drug development and continued fundamental research into the causes and mechanisms of genetic diseases. This tool is used in laboratories around the world to study gene function.

Much of the genetic disease is in the pipeline, which will be treated with gene scissors in the future, including some cancers, cystic fibrosis and haemophilia.

Scheele Prize The Pharmaceutical Association distributes every two years. The aim is to abolish current research on drugs and the creation of networks between Sweden and the outside world in the field in the context of a symposium on awarding prizes.

Source link